Delving into the Latest Updates on China Resources Angde Biotech Pharma Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Nervous System Diseases

Respiratory Diseases

Colony-stimulating factors

Interleukins

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Nervous System Diseases	1

Top 5 Drug Type	Count

Colony-stimulating factors	2
Interleukins	1
Enzyme	1

Top 5 Target	Count

EPO receptor(Erythropoietin receptor)	2
IL-11RA(Interleukin 11 receptor alpha)	1
PLG(Plasminogen)	1

[Translation] Phase II clinical study on the efficacy, safety, pharmacokinetics and pharmacodynamics of the optimal dose and administration regimen of polyethylene glycol recombinant human erythropoietin injection (CHO cells) for maintenance treatment in patients with renal anemia undergoing regular dialysis

主要研究目的：探索规律透析肾性贫血患者转换为聚乙二醇重组人促红素注射液（CHO细胞）维持治疗的最佳剂量和给药方案。次要研究目的：（1）评价聚乙二醇重组人促红素注射液（CHO细胞）在规律透析肾性贫血患者中长期用药的有效性和安全性；（2）评价聚乙二醇重组人促红素注射液（CHO细胞）在规律透析肾性贫血患者中的药代动力学、药效学及免疫原性特征。

[Translation]

Main study objectives: To explore the optimal dose and administration regimen for patients with renal anemia undergoing regular dialysis to switch to maintenance therapy with polyethylene glycol recombinant human erythropoietin injection (CHO cells). Secondary study objectives: (1) To evaluate the efficacy and safety of polyethylene glycol recombinant human erythropoietin injection (CHO cells) in patients with renal anemia undergoing regular dialysis; (2) To evaluate the pharmacokinetic, pharmacodynamic and immunogenic characteristics of polyethylene glycol recombinant human erythropoietin injection (CHO cells) in patients with renal anemia undergoing regular dialysis.

Start Date14 Apr 2022

Sponsor / Collaborator

China Resources Angde Biotech Pharma Co., Ltd.

NCT05629598

/ Unknown statusPhase 2

A Phase Ⅱ Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Polyethylene Glycol Recombinant Human Erythropoietin Injection (CHO Cell) in Optimal Dose and Administration Regimen for Maintenance Therapy in Patients With Regular Dialysis Renal Anemia.

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.

Start Date13 Apr 2022

Sponsor / Collaborator

China Resources Angde Biotech Pharma Co., Ltd.

NCT05295173

/ CompletedPhase 3

A Phase III, Multicenter, Randomized, Blind Endpoint and Positive Drug Control Study of Recombinant Human Tissue Plasminogen Kinase Derivatives for Injection in the Treatment of Patients With Acute Ischemic Stroke

The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.

Start Date21 Mar 2022

Sponsor / Collaborator

China Resources Angde Biotech Pharma Co., Ltd.

[+1]

100 Clinical Results associated with China Resources Angde Biotech Pharma Co., Ltd.

Login to view more data

0 Patents (Medical) associated with China Resources Angde Biotech Pharma Co., Ltd.

Login to view more data

7

Literatures (Medical) associated with China Resources Angde Biotech Pharma Co., Ltd.

01 Aug 2025·Journal of Biotechnology

Glutamate-related nitrogen metabolism regulates cold-adaptive synthesis of red pigment in polar fungus Geomyces sp. WNF-15A

Article

Author: Wang, Nengfei ; Guo, Yan ; Zhou, Xiangshan ; Cai, Menghao ; Long, Haoyu ; Liu, Haifeng ; Lu, Jian ; Zhou, Jiawei

The polar fungus Geomyces sp. WNF-15A produces high-quality red pigment (AGRP), but the cold-dependent characteristic of AGRP synthesis restricts its industrialization. This study employed transcriptome analysis to compare gene expression profiles of the wild-type strain with cold-independent mutants of scaffold1.t692 (Δ1-692) and scaffold2.t704 (Δ2-704). From the analysis, 23 candidate genes were identified and functionally characterized among 22,600 differentially expressed genes. Knockout and recovery of scaffold5.t61, scaffold7.t586, or scaffold7.t712 proved their regulatory functions in AGRP synthesis, among which scaffold5.t61 functioned as a transcription factor, while scaffold7.t586 and scaffold7.t712 were involved in the glutamate-related nitrogen metabolism. Exogenous addition of nitrate, glutamine, and glutamate, combined with transcriptional regulation studies, revealed the importance of glutamate metabolism for cold-adaptive synthesis of AGRP. Scaffold5.t61 responded to the cold environment and regulated the transcription of scaffold2.t704 and scaffold1.t692. It subsequently increased glutamate synthesis by regulating the key nitrogen metabolism genes of scaffold7.t586 and scaffold7.t712, ultimately resulting in cold-dependent synthesis of AGRP in Geomyces sp. WNF-15A. This study offers new insights into the mechanisms of cold adaptation in polar fungi and serves as a reference for the development of psychrophilic fungal resources.

20 Jan 2022·Journal of Industrial Microbiology and BiotechnologyQ3 · ENGINEERING & TECHNOLOGY

Transposon insertion mutation of Antarctic psychrotrophic fungus for red pigment production adaptive to normal temperature

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Huang, Hezhou ; Zhou, Xiangshan ; Zhang, Yuanxing ; Ding, Lulu ; Lu, Jian ; Lu, Fengning ; Cai, Menghao

AbstractPolar regions are rich in microbial and product resources. Geomyces sp. WNF-15A is an Antarctic psy chrotrophic filamentous fungus producing high quality red pigment with potential for industrial use. However, efficient biosynthesis of red pigment can only realize at low temperature, which brings difficult control and high cost for the large-scale fermentation. This study aims to develop transposon insertion mutation method to improve cell growth and red pigment production adaptive to normal temperature. Genetic manipulation system of this fungus was firstly developed by antibiotic marker screening, protoplast preparation and transformation optimization, by which transformation efficiency of ∼50% was finally achieved. Then transposable insertion systems were established using Helitron, Fot1, and Impala transposons. The transposition efficiency reached 11.9%, 9.4%, and 4.6%, respectively. Mutant MP1 achieved the highest red pigment production (OD520 of 39) at 14°C, which was 40% higher than the wild-type strain. Mutant MP14 reached a maximum red pigment production (OD520 of 14.8) at 20°C, which was about twofold of the wild-type strain. Mutants MP2 and MP10 broke the repression mechanism of red pigment biosynthesis in the wild-type and allowed production at 25°C. For cell growth, eight mutants grew remarkably better (12%∼30% biomass higher) than the wild-type at 25°C. This study established an efficient genetic manipulation and transposon insertion mutation platform for polar filamentous fungus. It provides reference for genetic breeding of psychrotrophic fungi from polar and other regions.

01 Nov 2021·Journal of BiotechnologyQ3 · ENGINEERING & TECHNOLOGY

High-level living cell production of cytidine-5′-diphosphocholine in metabolically engineered yeast

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Zhang, Yuanxing ; Liu, Qi ; Ren, Yanna ; Liu, Haifeng ; Cai, Menghao ; Zhou, Xiangshan

Industrial production of neuroprotective drug CDP-choline is accomplished via permeabilized or lysed cell biotransformation because of the inefficient penetration of substrates into intact cells. We previously proposed a novel one-step living cell method for CDP-choline production by engineered yeast, but obtained low titer and molar yield. This study develops a high-production strain with improved molar yield by metabolic engineering strategies. The selective markers previously integrated into host cell were recovered for facilitating genetic modification, which however resulted a strain with improved CDP-choline titer and molar yield to CMP. Knockout of 5'-NT or CDA in CMP sinking pathway but not APY in CTP sinking pathway further improved CDP-choline titer and molar yield to CMP. However, overexpression of seven enzymes in CTP synthetic pathway showed no positive functions. Finally, optimization of CMP and choline phosphate levels for the optimized recombinant strains achieved a high-level CDP-choline of ~30 g/L, which was enhanced by 400% compared to the previous work. Also, the molar yield of CDP-choline to CMP increased from 40% to 84.7%. The titer and molar yield are comparable to the reported permeabilized or lysed cell based biotransformation methods. It represents a novel and competitive paradigm for the potential industrial production of CDP-choline.

100 Deals associated with China Resources Angde Biotech Pharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with China Resources Angde Biotech Pharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

3

Approved

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human erythropoietin(China Resources Angde) ( EPO receptor )	Anemia More	Approved
Recombinant human tissue-type plasminogen activator derivative(China Resources Angde Biotech Pharma) ( PLG )	Acute Ischemic Stroke More	Approved
Recombinant human interleukin-11(China Resources Angde Biotech) ( IL-11RA )	Thrombocytopenia More	Approved
Recombinant Peglated human erythropoietin(China Resources Angde Biotech Pharma Co., Ltd.) ( EPO receptor )	Anemia of renal disease More	Phase 2
Recombinant hirudin(China Resources Angde Biotech Pharma Co., Ltd.) ( prothrombin )	Thrombosis More	Pending